TY - JOUR
T1 - Caffeine combined with sedative/anesthetic drugs triggers widespread neuroapoptosis in a mouse model of prematurity
AU - Cabrera, Omar Hoseá
AU - O’Connor, Shawn David
AU - Swiney, Brant Stephen
AU - Salinas-Contreras, Patricia
AU - Manzella, Francesca Maria
AU - Taylor, George Townsend
AU - Noguchi, Kevin Kiyoshi
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017
Y1 - 2017
N2 - Objectives: Caffeine (CAF) and sedative/anesthetic drugs (SADs) are often coadministered to premature infants in the neonatal intensive care unit (NICU). While SAD neurotoxicity in the developing brain is well established, it is not fully clear whether CAF interacts with SADs and whether this interaction is detrimental. Using a mouse model of prematurity, we hypothesized that CAF would increase apoptotic neurotoxicity when coadministered with SADs. Methods: Postnatal day 3 mice were treated with vehicle or 80 mg/kg CAF prior to challenge with 6 mg/kg midazolam, 40 mg/kg ketamine, or 40 lg/kg fentanyl. Six hours later, pups were sacrificed for activated caspase 3 (AC3) immunohistochemistry, and number of AC3 positive cells per mm3 throughout neocortex, hippocampus, caudate, thalamus, and colliculi was analyzed. Results: CAF caused a statistically significant increase in AC3 positive cells when coadministered with midazolam (p = 0.002), ketamine (p = 0.014), or fentanyl (p < 0.001). Our composite dataset suggests that the addition of CAF to these SADs has a supra-additive effect, causing more neurotoxicity than expected. Conclusions: CAF may augment the neurotoxic action of SADs indicated for neonatal sedation/ anesthesia in the NICU by triggering widespread apoptosis in the developing brains of premature infants.
AB - Objectives: Caffeine (CAF) and sedative/anesthetic drugs (SADs) are often coadministered to premature infants in the neonatal intensive care unit (NICU). While SAD neurotoxicity in the developing brain is well established, it is not fully clear whether CAF interacts with SADs and whether this interaction is detrimental. Using a mouse model of prematurity, we hypothesized that CAF would increase apoptotic neurotoxicity when coadministered with SADs. Methods: Postnatal day 3 mice were treated with vehicle or 80 mg/kg CAF prior to challenge with 6 mg/kg midazolam, 40 mg/kg ketamine, or 40 lg/kg fentanyl. Six hours later, pups were sacrificed for activated caspase 3 (AC3) immunohistochemistry, and number of AC3 positive cells per mm3 throughout neocortex, hippocampus, caudate, thalamus, and colliculi was analyzed. Results: CAF caused a statistically significant increase in AC3 positive cells when coadministered with midazolam (p = 0.002), ketamine (p = 0.014), or fentanyl (p < 0.001). Our composite dataset suggests that the addition of CAF to these SADs has a supra-additive effect, causing more neurotoxicity than expected. Conclusions: CAF may augment the neurotoxic action of SADs indicated for neonatal sedation/ anesthesia in the NICU by triggering widespread apoptosis in the developing brains of premature infants.
KW - Apoptosis
KW - Caffeine
KW - Fentanyl
KW - Ketamine
KW - Midazolam
KW - Premature infant
UR - http://www.scopus.com/inward/record.url?scp=85001944872&partnerID=8YFLogxK
U2 - 10.1080/14767058.2016.1261400
DO - 10.1080/14767058.2016.1261400
M3 - Article
C2 - 27924651
AN - SCOPUS:85001944872
SN - 1476-7058
VL - 30
SP - 2734
EP - 2741
JO - Journal of Maternal-Fetal and Neonatal Medicine
JF - Journal of Maternal-Fetal and Neonatal Medicine
IS - 22
ER -